If I was dying of cancer I would want the fda to let me try whatever drug I wanted regardless of efficacy.
-
-
-
they already do that! exactly what my link is about. however, after they do that, they should do proper trials with overall survival improvement focus -- which most don't do
Kraj razgovora
Novi razgovor -
-
-
Have you read any of Alex Tabarrok's voluminous writing on this subject? You might revisit this take.
-
any links?
- Još 1 odgovor
Novi razgovor -
-
-
Not sure that’s the right conclusion, though. In 40% of trials, they saw a surrogate metric improve (which still sounds kind of good?), and another 25% of tests hadn’t finished yet.
-
Surrogate metrics are excellent if you're a pharmaceutical company, meaningless if you're a patient, and can go either way for researchers depending on their goals (patient care v. careerism). For a good overview see https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0902-9 … or just follow
@VPrasadMDMPH - Još 3 druga odgovora
Novi razgovor -
-
-
This is the wrong conclusion: the overall feedback loop needs to be *faster*, not slower. This will help get working treatments to patients faster (saving lives) while also enabling us to "filter out" treatments that don't work quicker (also saving lives).
-
What does speed of the feedback loop have to do with the outcome? I agree that the FDA should be faster — at rejecting drugs that don't work.
Kraj razgovora
Novi razgovor -
-
-
Main issue is not the approval-see associated commentary-
#FDA continued one#drug’s approval even though the confirmatory#trial actually confirmed that the drug did not improve either survival or quality of life.#oncology#healthcare#innovationhttp://bit.ly/2RA7PhNHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
-
-
People should stop giving policy advice without considering the importance of both false positives and false negatives in a particular case
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.